ClinicalTrials.gg
RecruitingNCT06576128Updated Nov 10, 2026

Ultrasound-Guided Transversus Abdominis Plan (TAP) Block in Endovascular Cardiac Interventions

An interventional study of ultrasound and parenteral local anesthesia in Anesthesiology, Percutaneous Coronary Intervention and Cardiac Catheterization, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 131 studies in Patient Satisfaction with a site in Turkey — 32 open to participants now, 33 under way, none of them phase 3. Patient Satisfaction · Turkey.

Planned enrollment
40th of 102
100 · median 90
Started
2024
with 12 others
No phase
102 of 131
26 open now
Primary completion
2027-10
later than 32 of 32 live
Registered
73rd of 131
by date
Lead sponsor
7 of 131
Istanbul University - Cerrahpasa

Among the 131 studies in Patient Satisfaction with a site in Turkey, this one is the 40th largest by planned enrollment of the 102 interventional ones that give a count, is one of 13 that started in 2024, is one of 102 with no phase, reaches primary completion later than 32 of the 32 other live ones, and was the 73rd registered.

Patient Satisfaction

882 studies on the registry are indexed under Patient Satisfaction; 205 are open to participants now.

Browse Patient Satisfaction studies →

Open to participants now

32 of the 131 studies in Patient Satisfaction with a site in Turkey are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 102 Patient Satisfaction studies recruiting now, 63 (62%) set no upper age limit and 31 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Patient Satisfaction with a site in Turkey, or all of them as a file.
02

Study summary

Sensory innervation of the femoral region which is the entry point for endovascular cardiac interventions such as coronary angiography,cardiac catheterization and percutaneous coronary intervention is complex.It is thought that the ilioinguinal and iliohypogastric nerves contribute mostly.With transversus abdominis plane block(TAPB),it is planned to provide analgesia by creating a block in these nerve branches that contribute to the sensory innervation of the intervention area.In addition;it was aimed to investigate patient's and physician's satisfaction during the procedure.

Read the detailed description

Cardiac catheterization was first performed by Werner Frossman in the late 1920s, when the ureteral catheter was advanced in the antecubital vein and demonstrated by fluoroscopy in the right atrium. Over the years, this method was developed; It has been used for more specific and complicated clinical situations.

Coronary angiography was first used for diagnostic purposes in the 1950s. It has continued to exist as a gold standard method in the diagnosis and treatment of coronary artery diseases and some other cardiac pathologies until today.

For endovascular cardiac interventions; femoral, brachial and radial arteries are used. Blood loss and difficulty in achieving hemostasis are harder in femoral artery interventions than other arteries. However, it has been observed that the femoral artery is more frequently preferred in endovascular cardiac interventions. The reason is that the artery has a large lumen (approximately 8-9 mm) and continues after the abdominal aorta and iliac artery. One of the most important reasons for this is that there is very little anatomical variation. The femoral artery can be felt approximately 1/3 medial to the inguinal ligament.After the inguinal ligament, the iliac artery, commonly it is called the femoral artery. Femoral artery is mostly preferred in cardiac interventions. Because this region has common iliac artery it is thought to be safer because it comes before the bifurcation of the femoral artery and after the inferior epigastric artery.

Transversus abdominis plane block (TAPB) aims to block the ilioinguinal and iliohypogastric nerves. In gynecological, urological surgeries, colorectal surgeries, cholecystectomies and inguinal surgeries; it has been used to provide intraoperative and postoperative analgesia.

The transversus abdominis plane is between the internal oblique muscle and the transversus abdominis muscle. In this plane, ilioinguinal and iliohypogastric nerves are located together. Ilioinguinal and iliohypogastric nerves originate from the ventral branches of L1 and in some variations, T12 may also contribute. The sensory innervation of the femoral region where endovascular cardiac interventions are performed is complex. It is thought that the ilioinguinal and iliohypogastric nerves contribute mostly. TAPB aims to provide analgesia by creating a block in these nerve branches that contribute to the sensory innervation of the intervention area.

03

Conditions studied

  • Anesthesiology
  • Percutaneous Coronary Intervention
  • Cardiac Catheterization
  • Analgesia
  • Satisfaction, Patient

Browse trials for

Keywords

  • ultrasonography
  • anesthesiology
  • transversus abdominis plane block
  • Percutaneous Coronary Intervention
  • Cardiac Catheterization
  • analgesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is over 18 years of age
  • Coronary angiography, cardiac catheterization and percutaneous coronary intervention will be applied to the patient,
  • The above-mentioned procedures will be taken under elective conditions,
  • Providing an optimal image when imaging the patient with ultrasound,
  • \< 1.5
  • If the patient gives consent, S/he will be included in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years of age,
  • Patients treated under emergency conditions,
  • morbid obesity (>35 kg/m2),
  • pregnant women,
  • (NYHA) stage 4 patients with advanced decompensated heart failure,
  • Patients with symptoms such as redness, temperature increase, infection, hematoma in the application area before the procedure,
  • Patients with a history of allergy to local anesthetics,
  • Patients who cannot be communicated,
  • Those with severe psychosis or progressive neurological deficits and muscle disease,
  • Patients who do not consent to the application will be excluded from the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Sham comparator
    control group

    only local anesthesia will be applied to surgical field as a part of the routine procedure.

    Procedure: parenteral local anesthesia

  • Active comparator
    block group

    local anesthesia will be applied to surgical field as a part of the routine procedure and additionally transversus abdominisl plane block will be applied.

    Device: ultrasound

Interventions

  • Deviceultrasound

    In additional to local anesthesia, 10 ml lidocaine (2%) (Lidon, Onfarma, Turkey ), TAPB will be performed under ultrasound imaging..

  • Procedureparenteral local anesthesia

    As routine procedure; the cardiologist will palpate the right or left femoral artery under sterile conditions and apply approximately 10 ml lidocaine (2%) to this area as local anesthesia (Lidon, Onfarma, Turkey ). Then, a puncture will be made on the anterior wall of the femoral artery with an 18 G needle . Approximately 3-4 mm skin incision will be made with the number 11 scalpel tip and the Seldinger technique will be continued. 6F femoral sheath to be placed, cardiac The catheterization process will begin.

06

What researchers measure

Primary outcomes

  1. measuring the analgesic efficacy of TAPB

    The pain will be assessed by the Numeric Rating Scale-11(NRS -11) to measure the analgesic efficacy of TAPB. Minimum pain score is point zero, maximum pain score is ten points.Minimum pain scores (NRS is less than 4 points) will have positive outcomes.

    Time frame: 4 months

  2. For patient and physician satisfaction;5-point Likert scale will be used. Minimum satisfaction score is one point, maksimum satisfaction score is five points.Higher scores have positive outcomes.

    One point represents strongly unsatisfied and 5 points represent strongly satisfied.

    Time frame: 4 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Oct 2027, 37 months after the start.

Of 368 non-industry interventional studies with no phase under Patient Satisfaction, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 37 months is above that.

Counting every sponsor, half of 370 studies reached it within 12 months; a quarter within 6 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2026 → Oct 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Aug 28, 2024
StartActual
Sep 10, 2024
Primary completionEst.
Oct 15, 2027was Oct 2026
CompletionEst.
Dec 15, 2027was Dec 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 15, 2026→Oct 15, 2027
Nov 10, 2026
Study completion
Dec 15, 2026→Dec 15, 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Oct 15, 2026→Oct 15, 2027
    Study completion Dec 15, 2026→Dec 15, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06576128
Responsible party
Kerem Erkalp, MD, Prof (proffessor, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Aug 28, 2024
Start date
Sep 10, 2024
Primary completion
Oct 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Gozde Altun
Contact
gozde.altun@iuc.edu.tr
+905544290333
Kerem Erkalp
Contact
keremerkalp@hotmail.com
+905327879500
Kerem Erkalp
study chair · Proffessor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion